In the future studies, comparisons of the clinical characteristics of various demyelinating diseases (e.g., MOGAD, MS, and AQP4-ab-positive NMOSD) in a multicenter cooperation and with a large sample size and long follow-up time are needed. This evidence concerns the gene AQP4 and myeloid sarcoma.